— Pharmaceutical Medicine & Drug Development

Darren Wogman — Pharmaceutical Medicine & Drug Development (UK)

Publications indexed from PubMed, Google Scholar, and institutional repositories — updated as new work is published.

A working archive of peer-reviewed publications in pharmaceutical medicine and drug development. Auto-updated, indexed, and organized so the work stays findable.

/ Recent Publications

Active work, as published

Drug Development
Pharmacovigilance
Regulatory Science

Phase II adaptive trial design in oncology drug candidates

Signal detection methods in post-market safety surveillance

Benefit-risk assessment frameworks in pharmaceutical licensing

Journal of Clinical Pharmacology · 2024. Peer-reviewed. Examines adaptive endpoints in early-phase oncology trials with application to regulatory submission frameworks.

Drug Safety · 2024. Peer-reviewed. Comparative analysis of disproportionality algorithms applied to spontaneous adverse event reporting databases.

British Journal of Clinical Pharmacology · 2023. Peer-reviewed. Reviews structured decision frameworks used across EMA and FDA regulatory submissions.

Wide shot of a laboratory bench under cool overhead fluorescent light, left-side framing with generous negative space to the right — printed research documents and a spiral-bound protocol binder visible in the foreground, a researcher's hands annotating a page with a pen, data printout partially legible in the background
Wide shot of a laboratory bench under cool overhead fluorescent light, left-side framing with generous negative space to the right — printed research documents and a spiral-bound protocol binder visible in the foreground, a researcher's hands annotating a page with a pen, data printout partially legible in the background
+ Research Areas

Browse the archive by domain

Work organized by thematic area — navigate to the drug development domain most relevant to your search, or use the full publications index.

Clinical Pharmacology & Trial Design

Pharmacovigilance & Safety Science

Regulatory Affairs & Benefit-Risk

Drug Development Strategy